| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 13 Nov 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
As described in Item 5.03, which is incorporated by reference into this Item 3.03, Mangoceuticals, Inc. (the “Company”) amended its Series B and Series C preferred stock designations effective November 9, 2026, and established its Series... |
| 12 Nov 2026 | 1-A |
| 06 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Shareholder Director Nominations +1 more
On November 2, 2026, the holder of all 50 issued and outstanding shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”) of Mangoceuticals, Inc. (the “Company”), acting by written consent in lieu of a meeting, app... |
| 06 Nov 2026 | PRE 14A |
| 09 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
This Securities Purchase Agreement (this “Agreement”) is dated as of October 8, 2026 between Mangoceuticals, Inc., a Texas corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succ... |
| 09 Oct 2026 | 424B5 |
| 06 Oct 2026 |
Form 4: Cohen Jacob D., Director and 1 other
Gave 500,000 shares as a gift · Acquired 500,000 shares (Gift) · Disposed of 0 Convertible Promissory Note (Other Transaction) · 3 more |
| 06 Oct 2026 |
Form 4: Johnston Eugene M, CFO
Received 100,000 shares as a grant or award |
| 06 Oct 2026 |
Form 4: Hamilton Alex P., Director
Received 100,000 shares as a grant or award |
| 06 Oct 2026 | SCHEDULE 13D/A |
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
This Agreement has been executed by the individual or entity whose name is set forth under Section I of “Subscriber Information” below (the “Subscriber”), in connection with the Subscriber’s subscription to purchase ___________ Membershi... |
| 21 Aug 2026 |
8-K: Termination of a Material Definitive Agreement
Re: Mutual Termination of Business Combination Agreement dated July 29, 2026 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 425 |
| 06 Aug 2026 | 425 |
| 04 Aug 2026 | 425 |
| 04 Aug 2026 |
8-K: Other Events
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination |
| 30 Jul 2026 | 425 |
| 30 Jul 2026 | 425 |
Loading...